Literature DB >> 29437872

Mathematical and Experimental Validation of Flux Dialysis Method: An Improved Approach to Measure Unbound Fraction for Compounds with High Protein Binding and Other Challenging Properties.

J Cory Kalvass1, Colin Phipps2, Gary J Jenkins2, Patricia Stuart2, Xiaomei Zhang2, Lance Heinle2, Marjoleen J M A Nijsen2, Volker Fischer2.   

Abstract

A flux dialysis method to measure unbound fraction (fu) of compounds with high protein binding and other challenging properties was tested and validated. This method is based on the principle that the initial flux rate of a compound through a size-excluding dialysis membrane is proportional to the product of the compound initial concentration, fu, and unbound dialysis membrane permeability (Pmem). Therefore, fu can be determined from the initial concentration and flux rate, assuming membrane Pmem is known. Compound initial flux rates for 14 compounds were determined by dialyzing human plasma containing compound (donor side) versus compound-free plasma (receiver side) and measuring the rate of compound appearance into the receiver side. Eleven compounds had known fu values obtained from conventional methods (ranging from 0.000013 to 0.22); three compounds (bedaquiline, lapatinib, and pibrentasvir) had previously qualified fu values (e.g., <0.001).Pmem estimated from flux rates and known fu values did not meaningfully differ among the compounds and were consistent with previously published values, indicating that Pmem is a constant for the dialysis membrane. This Pmem constant and the individual compound flux rates were used to calculate fu values. The flux dialysis fu values for the 11 compounds were in good agreement with their reported fu values (all within 2.5-fold; R2 = 0.980), confirming the validity of the method. Furthermore, the flux dialysis method allowed discrete fu to be estimated for the three compounds with previously qualified fu Theoretical and experimental advantages of the flux dialysis method over other dialysis-based protein binding methods are discussed.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29437872     DOI: 10.1124/dmd.117.078915

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.

Authors:  Ahmed Hamed Salem; Nimita Dave; Thomas Marbury; Beibei Hu; Dale Miles; Suresh K Agarwal; Orlando F Bueno; Rajeev M Menon
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

2.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

3.  Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound.

Authors:  William J Jusko; Emilie A G Molins; Vivaswath S Ayyar
Journal:  Drug Metab Dispos       Date:  2020-08-05       Impact factor: 3.922

4.  Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution.

Authors:  Estelle Yau; Andrés Olivares-Morales; Michael Gertz; Neil Parrott; Adam S Darwich; Leon Aarons; Kayode Ogungbenro
Journal:  AAPS J       Date:  2020-02-03       Impact factor: 4.009

5.  Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice.

Authors:  Minjee Kim; Janice K Laramy; Afroz S Mohammad; Surabhi Talele; James Fisher; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-01-31       Impact factor: 3.922

Review 6.  Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Authors:  Minjee Kim; Sani H Kizilbash; Janice K Laramy; Gautham Gampa; Karen E Parrish; Jann N Sarkaria; William F Elmquist
Journal:  Pharm Res       Date:  2018-07-12       Impact factor: 4.200

7.  Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.

Authors:  Matthew P Kosloski; Haoyu Wang; David Pugatch; Federico J Mensa; Edward Gane; Eric Lawitz; Thomas C Marbury; Richard A Preston; Jens Kort; Wei Liu
Journal:  Eur J Clin Pharmacol       Date:  2018-10-19       Impact factor: 2.953

8.  To tolerate or to agree: A tutorial on tolerance intervals in method comparison studies with BivRegBLS R Package.

Authors:  Bernard G Francq; Marion Berger; Charles Boachie
Journal:  Stat Med       Date:  2020-09-23       Impact factor: 2.373

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.